SEVER LIFE SCIENCES B.V. WIRD ÜBER IHRE TOCHTERGESELLSCHAFT NORDIC PHARMA, INC. PATIENTENDATEN UND DIE ERGEBNISSE EINER STUDIE ZUR PATIENTENERFAHRUNG MIT LACRIFILL® CANALICULAR GEL, EINER NEUARTIGEN THERAPIE ZUR KONTROLLE DER AUGENOBERFLÄCHE, IM RAHMEN DER TAGUNG DER AMERICAN ACADEMY OF OPHTHALMOLOGY (AAO) 2026 VORSTELLEN

Nordic Pharma says more than 2,200 U.S. eye-care practices use LACRIFILL Canalicular Gel and over 130,000 patients have been treated. In the company’s patient survey, 96% of respondents who had cataract surgery in the prior six months and 91% of all respondents said their eyes felt better; 83% of recently operated patients who received at least one treatment reported less discomfort. The company plans to present patient data and survey findings at the American Academy of Ophthalmology meeting on October 9–12, 2026; the reported survey results are company-provided.

Analysis

The investable signal is commercial validation, not clinical proof: reported practice adoption and treated-patient counts suggest the product has moved beyond a launch-only stage, but neither establishes repeat utilization, revenue contribution, or durable patient benefit. The satisfaction figures are company-sponsored, self-reported, and lack sample size, response rate, comparator, and methodology; treat them as promotional evidence until the AAO presentation supplies those details. The stated reduction in reliance on drops could pressure incumbent dry-eye therapies at the margin if independently confirmed, while also potentially expanding treatment uptake among patients seeking alternatives. That substitution case is not yet strong enough to underwrite a position in competitors. The AAO demonstration is an immediate awareness and ordering catalyst; the more important 1–3 month checks are post-meeting adoption, reorder rates, and any disclosed reimbursement or practice-level economics. Over 6–18 months, repeat use and evidence of sustained benefit would matter more than conference visibility. SEVER Life Sciences and Nordic Pharma are privately held, and no public ticker is supplied, so there is no direct equity expression. The main contrarian point: the headline adoption counts may look compelling while concealing low utilization per practice or weak economics. A weak or absent follow-through in repeat orders would falsify the commercial traction thesis.

Key Decisions for Investors

• No immediate public-equity trade: the product owner is private, and the release does not provide enough evidence to establish a material read-through to any listed company.
• Use AAO as a diligence catalyst, not a price catalyst: monitor the presentation for study design, sample size, response rate, comparator, duration of benefit, and whether results are independently evaluated.
• Place a commercial alert on repeat orders, active-use rates per practice, reimbursement/access, and revenue contribution. Adoption counts without these measures do not establish scalable economics.
• Keep listed dry-eye treatment providers, including AbbVie, Bausch + Lomb, and Viatris, on a watchlist rather than shorting them; consider a competitive-impact view only if independent evidence confirms sustained drop substitution at meaningful scale.
• Reassess over the next 1–3 months. The thesis weakens if post-conference ordering and repeat utilization fail to follow reported adoption, or if subsequent evidence does not support durable symptom relief.